Interstitial Lung Disease

Healio Pulmonology has you covered. The Editors have compiled a list of popular articles posted on Healio Pulmonology in October.

NEW ORLEANS — Patients with pulmonary fibrosis who are at risk for pulmonary hypertension experienced improvements in physical activity after treatment with inhaled nitric oxide, according to a study presented at the CHEST Annual Meeting.

Comparative serum protein biomarker profiling may allow researchers to identify patients with rheumatoid arthritis-associated interstitial lung disease and/or idiopathic pulmonary fibrosis, according to findings published in Arthritis Rheumatology.

Boehringer Ingelheim announced that the FDA has granted nintedanib breakthrough therapy designation for chronic fibrosing interstitial lung disease with a progressive phenotype, according to a press release.

Pirfenidone treatment was associated with improvement in several outcomes among patients with progressive fibrosing unclassifiable interstitial lung disease, according to a new study.

When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress.

In September, the FDA approved the first treatment for a rare pulmonary disease, issued warnings for patients, providers and manufacturers and stepped up its efforts to investigate the outbreak of lung injuries related to the use of electronic cigarettes.

The FDA issued a safety alert today indicating that three drugs used to treat some patients with advanced breast cancer may cause rare but severe lung inflammation.

The FDA has approved nintedanib capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, according to a press release.